Ovid Therapeutics Inc
NASDAQ:OVID
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.7
4.04
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Ovid Therapeutics Inc
Wall Street
Price Targets
OVID Price Targets Summary
Ovid Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
OVID
is 3.33 USD
with a low forecast of 1.31 USD and a high forecast of 5.25 USD.
OVID Last Price Targets
Ovid Therapeutics Inc
The latest public price target was made on Jul 2, 2024 by
Raghuram Selvaraju
from
H.C. Wainwright
,
who expects
OVID
stock to
rise by 142%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Raghuram Selvaraju
H.C. Wainwright
|
3
USD
Upside 142% |
4 months ago
Jul 2, 2024
|
H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
StreetInsider
|
|
Thomas Shrader
BTIG
|
11
USD
Upside 787% |
5 months ago
May 20, 2024
|
BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
StreetInsider
|
Francois Brisebois
Oppenheimer
|
8
USD
Upside 545% |
5 months ago
May 14, 2024
|
Oppenheimer Reiterates Outperform Rating on Ovid Therapeutics Inc (OVID)
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is OVID's stock price target?
Price Target
3.33
USD
According to Wall Street analysts, the average 1-year price target for
OVID
is 3.33 USD
with a low forecast of 1.31 USD and a high forecast of 5.25 USD.
What is Ovid Therapeutics Inc's Revenue forecast?
Projected CAGR
326%
The
compound annual growth rate
of Ovid Therapeutics Inc's revenue for the next 3 years is
326%.
You don't have any saved screeners yet
